title: Effect of Helicobacter pylori eradication and antisecretory maintenance therapy on peptic ulcer recurrence in cirrhotic patients: a prospective, cohort 2-year follow-up study.
abstract: BACKGROUND
  The role of Helicobacter pylori eradication to cure peptic ulcer disease in patients with cirrhosis is not clear.
  
  
  OBJECTIVE
  To investigate the course of peptic ulcer disease in cirrhotics, first after healing with either H. pylori eradication or omeprazole therapy and second while on omeprazole maintenance therapy after recurrence.
  
  
  METHODS
  Prospective cohort study in a tertiary-care hospital in Greece. Out of 365 consecutive cirrhotic patients who underwent endoscopy, 67 had peptic ulcer and 30 were enrolled. H. pylori positive patients received eradication therapy and H. pylori negative patients received omeprazole treatment. Follow-up endoscopies were performed at 12 and 24 months or when symptoms recurred. Patients with ulcer recurrence were treated with omeprazole maintenance therapy. The main outcome measurement of the study was peptic ulcer relapse rate during follow-up.
  
  
  RESULTS
  Twenty-eight patients with healed ulcers were followed for up to 2 years. During follow-up, ulcer relapsed in 17 patients (8/18 H. pylori positive and 9/10 H. pylori negative at study entry, P=0.041), including 2 patients who died from ulcer bleeding. No further ulcer relapse was observed in the remaining 15 patients who received omeprazole maintenance therapy for the rest of follow-up. H. pylori negative status (P=0.002) and severity of cirrhosis (P=0.015) at study entry were independently related to shorter peptic ulcer relapse-free time.
  
  
  CONCLUSIONS
  H. pylori eradication does not protect all cirrhotics from ulcer recurrence and the majority of ulcers recur in H. pylori negative patients. Therefore, omeprazole maintenance treatment is mandatory, irrespectively of H. pylori status.
authors.affiliation: 1st Department of Gastroenterology, Evangelismos Hospital, Athens, Greece.
authors.forename: Charalambos
authors.initials: C
authors.lastname: Tzathas
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Triantafyllou
authors.forename: Elias
authors.initials: E
authors.lastname: Mallas
authors.forename: George
authors.initials: G
authors.lastname: Triantafyllou
authors.forename: Spiros D
authors.initials: SD
authors.lastname: Ladas
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D004724:Endoscopy; D005500:Follow-Up Studies; D006115:Greece / Q000453:epidemiology; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D010437:Peptic Ulcer / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D011446:Prospective Studies; D055502:Secondary Prevention; D012720:Severity of Illness Index
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D009853:Omeprazole